Zuclopenthixol

Zuclopenthixol (brand name Clopixol) is a first-generation thioxanthene antipsychotic used for schizophrenia and acute psychotic episodes, particularly when management of agitation or aggression is a priority. It is available in oral, short-acting injectable (Acuphase), and long-acting depot formulations and is more widely used in Europe, Canada, and Australia than in the US.

Like haloperidol, zuclopenthixol is a potent D2 antagonist with significant risk of EPS and other dose-related side effects. CYP2D6 phenotype is the principal pharmacogenetic factor in zuclopenthixol response.

CYP2D6 is the dominant enzyme clearing zuclopenthixol. Reduced CYP2D6 activity slows zuclopenthixol clearance, raising plasma concentrations at any given dose and increasing dose-related side effects, particularly EPS and sedation.

CYP2D6 ultrarapid metabolizers clear zuclopenthixol more rapidly and may have inadequate response at standard doses.

The clinical pattern mirrors haloperidol. CYP2D6 poor metabolizers reach higher zuclopenthixol concentrations and have higher rates of EPS; intermediate metabolizers fall in between. Ultrarapid metabolizers may need higher doses or an alternative agent.

CYP2D6 Normal Metabolizer

• Effect: Standard clearance and exposure.
• Recommendation: Standard dosing.

CYP2D6 Intermediate Metabolizer

• Effect: Reduced clearance; modestly elevated concentrations.
• Clinical consequence: Higher EPS risk.
• Recommendation: Reduce dose by ~25–50%, or select an alternative.

CYP2D6 Poor Metabolizer

• Effect: Markedly reduced clearance; substantially elevated concentrations.
• Clinical consequence: High risk of EPS and sedation.
• Recommendation: Reduce dose by ~50% or select an alternative antipsychotic.

CYP2D6 Ultrarapid Metabolizer

• Effect: Faster clearance; reduced exposure.
• Clinical consequence: Risk of inadequate response.
• Recommendation: Monitor response; titrate up if needed; consider alternative if response inadequate.

Indeterminate / Not Available

• Recommendation: Standard dosing; monitor for both efficacy and EPS.

Antipsychotics with less CYP2D6 dependence include olanzapine and quetiapine (CYP3A4-cleared). For CYP2D6 ultrarapid metabolizers needing rapid escalation, an alternative antipsychotic with a different metabolic pathway is often preferable.

• DPWG — Pharmacogenetics Working Group recommendations
• PharmGKB — Zuclopenthixol

Learn more about how genetics may affect your response to Zuclopenthixol and related medications:

• Haloperidol (Haldol) Side Effects: When CYP2D6 Genetics Are Behind Them
• Quetiapine (Seroquel) Side Effects: When CYP3A4 Genetics Make It Harder
• Zuclopenthixol (Clopixol) Side Effects: CYP2D6 Genetics Explained